Study · In silico · 2019

6 results

Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach.

Overgaard RV, Lindberg SØ, Thielke D

Diabetes, obesity & metabolism23 Aug 2018Cited by 26 (Europe PMC)

PMID30047216PMCIDPMC6585654DOI10.1111/dom.13479PepBankPUB-30047216

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

3 results from studies that gave the peptide. No result from this study comes from people.

01Computer modelIn silicoEfficacy outcome
In exposure-response simulations, switching from another GLP-1 receptor agonist to semaglutide 1.0 mg was associated with HbA1c reductions of about 0.3 to 0.8 percentage points.
In plain wordsIn computer simulations, switching to semaglutide 1.0 mg from another GLP-1 drug lowered HbA1c further.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change after switching to semaglutide 1.0 mg
Study
n: not reported in source
Exposure-response models of HbA1c and body weight (simulation)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.0 mgAs given in this study.
Source sentences
Summary
The potency-adjusted total effective GLP-1RA concentration increased after switching from another GLP-1RA to semaglutide and was associated with reductions ranging from ~0.3% to ~0.8%-points for HbA1c and from ~2% to ~4% for body weight with semaglutide 1.0 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
HbA1c and body weight time-course models were developed, using up to 30 weeks of observations from four trials in the semaglutide phase 3 programme.
Summary · context
After 26 weeks of simulated treatment with liraglutide, dulaglutide or exenatide extended-release, simulated semaglutide treatment was initiated 1 day after the last once-daily dose of liraglutide and 1 week after the last once-weekly doses of dulaglutide or exenatide extended-release.
Report a problemFND-3004721601
02Computer modelIn silicoEfficacy outcome
In exposure-response simulations, switching from another GLP-1 receptor agonist to semaglutide 1.0 mg was associated with body weight reductions of about 2% to 4%.
In plain wordsIn computer simulations, switching to semaglutide 1.0 mg from another GLP-1 drug lowered body weight further.
Peptide
Semaglutide
Outcome
DecreaseBody weight change after switching to semaglutide 1.0 mg
Study
n: not reported in source
Exposure-response models of HbA1c and body weight (simulation)
Outcome group
Body weight · Metabolic and weight
Studied dose
1.0 mgAs given in this study.
Source sentences
Summary
The potency-adjusted total effective GLP-1RA concentration increased after switching from another GLP-1RA to semaglutide and was associated with reductions ranging from ~0.3% to ~0.8%-points for HbA1c and from ~2% to ~4% for body weight with semaglutide 1.0 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
HbA1c and body weight time-course models were developed, using up to 30 weeks of observations from four trials in the semaglutide phase 3 programme.
Summary · context
After 26 weeks of simulated treatment with liraglutide, dulaglutide or exenatide extended-release, simulated semaglutide treatment was initiated 1 day after the last once-daily dose of liraglutide and 1 week after the last once-weekly doses of dulaglutide or exenatide extended-release.
Report a problemFND-3004721602
03Computer modelIn silicoEfficacy outcome
In exposure-response simulations, switching to semaglutide 0.25 mg from liraglutide or dulaglutide caused a temporary slight deterioration in HbA1c.
In plain wordsIn computer simulations, starting semaglutide at 0.25 mg after liraglutide or dulaglutide caused a short, slight rise in HbA1c.
Peptide
Semaglutide
Outcome
IncreaseTemporary HbA1c deterioration after switching to semaglutide 0.25 mg
Study
n: not reported in source
Exposure-response models of HbA1c and body weight (simulation)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.25 mgAs given in this study.
Source sentences
Summary
Temporary slight deteriorations in HbA1c were observed after switching to semaglutide 0.25 mg from liraglutide 1.2/1.8 mg or dulaglutide 1.5 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
HbA1c and body weight time-course models were developed, using up to 30 weeks of observations from four trials in the semaglutide phase 3 programme.
Summary · context
After 26 weeks of simulated treatment with liraglutide, dulaglutide or exenatide extended-release, simulated semaglutide treatment was initiated 1 day after the last once-daily dose of liraglutide and 1 week after the last once-weekly doses of dulaglutide or exenatide extended-release.
Report a problemFND-3004721603

Studies that did not test the peptide alone3

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

04Computer modelNot a test of Liraglutide aloneIn silicoEfficacy outcome
In exposure-response simulations, switching from pooled GLP-1 receptor agonists (liraglutide, dulaglutide, exenatide extended-release) to semaglutide was associated with HbA1c reductions.
In plain wordsIn computer simulations, switching from liraglutide or other GLP-1 drugs to semaglutide lowered HbA1c further. Liraglutide was the starting drug.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change after switching from a GLP-1RA to semaglutide
Study
n: not reported in source
Exposure-response models of HbA1c and body weight (simulation)
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The potency-adjusted total effective GLP-1RA concentration increased after switching from another GLP-1RA to semaglutide and was associated with reductions ranging from ~0.3% to ~0.8%-points for HbA1c and from ~2% to ~4% for body weight with semaglutide 1.0 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
HbA1c and body weight time-course models were developed, using up to 30 weeks of observations from four trials in the semaglutide phase 3 programme.
Summary · context
After 26 weeks of simulated treatment with liraglutide, dulaglutide or exenatide extended-release, simulated semaglutide treatment was initiated 1 day after the last once-daily dose of liraglutide and 1 week after the last once-weekly doses of dulaglutide or exenatide extended-release.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3004721604
05Computer modelNot a test of Liraglutide aloneIn silicoEfficacy outcome
In exposure-response simulations, switching from pooled GLP-1 receptor agonists (liraglutide, dulaglutide, exenatide extended-release) to semaglutide was associated with body weight reductions.
In plain wordsIn computer simulations, switching from liraglutide or other GLP-1 drugs to semaglutide lowered body weight further. Liraglutide was the starting drug.
Peptide
Liraglutide
Outcome
DecreaseBody weight change after switching from a GLP-1RA to semaglutide
Study
n: not reported in source
Exposure-response models of HbA1c and body weight (simulation)
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
The potency-adjusted total effective GLP-1RA concentration increased after switching from another GLP-1RA to semaglutide and was associated with reductions ranging from ~0.3% to ~0.8%-points for HbA1c and from ~2% to ~4% for body weight with semaglutide 1.0 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
HbA1c and body weight time-course models were developed, using up to 30 weeks of observations from four trials in the semaglutide phase 3 programme.
Summary · context
After 26 weeks of simulated treatment with liraglutide, dulaglutide or exenatide extended-release, simulated semaglutide treatment was initiated 1 day after the last once-daily dose of liraglutide and 1 week after the last once-weekly doses of dulaglutide or exenatide extended-release.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3004721605
06Computer modelNot a test of Liraglutide aloneIn silicoEfficacy outcome
In exposure-response simulations, switching to semaglutide 0.25 mg from liraglutide or dulaglutide caused a temporary slight HbA1c deterioration.
In plain wordsIn computer simulations, a switch from liraglutide or dulaglutide to a low semaglutide dose caused a short, slight rise in HbA1c.
Peptide
Liraglutide
Outcome
IncreaseTemporary HbA1c deterioration after switching to semaglutide 0.25 mg
Study
n: not reported in source
Exposure-response models of HbA1c and body weight (simulation)
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Temporary slight deteriorations in HbA1c were observed after switching to semaglutide 0.25 mg from liraglutide 1.2/1.8 mg or dulaglutide 1.5 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
HbA1c and body weight time-course models were developed, using up to 30 weeks of observations from four trials in the semaglutide phase 3 programme.
Summary · context
After 26 weeks of simulated treatment with liraglutide, dulaglutide or exenatide extended-release, simulated semaglutide treatment was initiated 1 day after the last once-daily dose of liraglutide and 1 week after the last once-weekly doses of dulaglutide or exenatide extended-release.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3004721606

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02054897

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 3883 Feb 2014 to 8 May 2015

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 12 Jun 2019

CompletedPhase 3Results postedNCT01885208

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 8132 Dec 2013 to 13 Jul 2015

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 13 Jun 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.